<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2013-02-27" updated="2019-12-02">
  <drugbank-id primary="true">DB08842</drugbank-id>
  <name>Acetylcarnitine</name>
  <description>Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India. Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. In human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine. The main role of acetylcarnitine is to help transport fatty acids into the mitochondrial matrix where fatty acid metabolism occurs.</description>
  <cas-number>3040-38-8</cas-number>
  <unii>6DH1W9VH8Q</unii>
  <average-mass>203.238</average-mass>
  <monoisotopic-mass>203.115758031</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7396</ref-id>
        <pubmed-id>15039515</pubmed-id>
        <citation>Vermeulen RC, Scholte HR: Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004 Mar-Apr;66(2):276-82.</citation>
      </article>
      <article>
        <ref-id>A7397</ref-id>
        <pubmed-id>16120381</pubmed-id>
        <citation>Ilias I, Manoli I, Blackman MR, Gold PW, Alesci S: L-Carnitine and acetyl-L-carnitine in the treatment of complications associated with HIV infection and antiretroviral therapy. Mitochondrion. 2004 Jul;4(2-3):163-8.</citation>
      </article>
      <article>
        <ref-id>A7398</ref-id>
        <pubmed-id>7813389</pubmed-id>
        <citation>Salvioli G, Neri M: L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res. 1994;20(4):169-76.</citation>
      </article>
      <article>
        <ref-id>A7399</ref-id>
        <pubmed-id>15591001</pubmed-id>
        <citation>Rebouche CJ: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004 Nov;1033:30-41.</citation>
      </article>
      <article>
        <ref-id>A7400</ref-id>
        <pubmed-id>15363640</pubmed-id>
        <citation>Virmani A, Binienda Z: Role of carnitine esters in brain neuropathology. Mol Aspects Med. 2004 Oct-Dec;25(5-6):533-49.</citation>
      </article>
      <article>
        <ref-id>A7401</ref-id>
        <pubmed-id>10877193</pubmed-id>
        <citation>Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, Greco AV: Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism. 2000 Jun;49(6):704-8.</citation>
      </article>
      <article>
        <ref-id>A7402</ref-id>
        <pubmed-id>19318118</pubmed-id>
        <citation>Barhwal K, Hota SK, Jain V, Prasad D, Singh SB, Ilavazhagan G: Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation. Neuroscience. 2009 Jun 30;161(2):501-14. doi: 10.1016/j.neuroscience.2009.02.086. Epub 2009 Mar 24.</citation>
      </article>
      <article>
        <ref-id>A7403</ref-id>
        <pubmed-id>17223507</pubmed-id>
        <citation>Wilson AD, Hart A, Brannstrom T, Wiberg M, Terenghi G: Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J Plast Reconstr Aesthet Surg. 2007;60(2):114-8. Epub 2006 Jul 24.</citation>
      </article>
      <article>
        <ref-id>A7404</ref-id>
        <pubmed-id>19620516</pubmed-id>
        <citation>Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G: Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension. 2009 Sep;54(3):567-74. doi: 10.1161/HYPERTENSIONAHA.109.132522. Epub 2009 Jul 20.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T15</ref-id>
        <isbn>978-0857111395</isbn>
        <citation>Brayfield, Alison (2014). Martindale : The Complete Drug Reference (38th ed.). Pharmaceutical Press.</citation>
      </textbook>
      <textbook>
        <ref-id>T13</ref-id>
        <isbn>978-1849736701</isbn>
        <citation>O'Neil, Maryadele J. (2013). The Merck Index : An Encyclopedia of Chemicals, Drugs, and Biologicals (15th ed.). Royal Society of Chemistry, The.</citation>
      </textbook>
    </textbooks>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Gu, Heng-da; Shi, Shuang; Yang, Ying; Shi, Zhao-xin; Yu, Zhan-long. Synthesis of acetyl-L-carnitine by direct acylation method. Shenyang Huagong Xueyuan Xuebao (2006), 20(2), 154-155, 160.</synthesis-reference>
  <indication>Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.&#13;
&#13;
 &#13;
</indication>
  <pharmacodynamics>The complete physiological effects of acetycarnitine are still being studied. What has been discovered so far is that acetylcarinitine has positive effects on mental fatigue, neurodegenerative disorders, cognitive functions, peripheral neuropathy, and sperm motility. Specifically, in one study involving patients with HIV, patients on acetylcarnitine supplementation had increased CD4 cells, decreased lymphocyte apoptosis, improved polyneuropathy and cardiovascular damage, and decreased triglyceride and TNF alpha levels in the blood. Another study showed that acetylcarnitine increased glucose disposal in type 2 diabetic patients through possibly increasing the activity of glycogen synthase.</pharmacodynamics>
  <mechanism-of-action>The mechanisms of action of acetylcarnitine have not been fully elucidated, but it seems that the main role of acetylcarnitine is to donate an acetyl group during fatty acid metabolism to help transport fatty acids, such as acetyl CoA, into the mitochondrial matrix where fatty acid metabolism occurs. Additionally several studies have found that separate from its metabolic role, acetylcarnitine has neuromodulatory, neurotrophic, and neuroprotective effects that most likely are involved in its positive effects in neurological diseases. In its role in treating male infertility, acetylcarnitine increases the active movement of sperm cells. One study has also mentioned a role for acetylcarnitine as an antioxidant. The study found that through the receptor, tyrosine kinase A, acetylcarnitine was able to decrease the production of free radicals, peroxidation of lipids, and oxidation of proteins as well as decrease glutathione levels and increase thioredoxin.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Acetylcarnitine supplements are absorbed in a similar manner to L-carnitine.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Acetylcarnitine is eliminated in a similar manner as L-carnitine. Both of which are eliminated by the kidneys and involve tubular secretion.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as acyl carnitines. These are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond.</description>
    <direct-parent>Acyl carnitines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Fatty Acyls</class>
    <subclass>Fatty acid esters</subclass>
    <alternative-parent>Amines</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Tetraalkylammonium salts</alternative-parent>
    <substituent>Acyl-carnitine</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Quaternary ammonium salt</substituent>
    <substituent>Tetraalkylammonium salt</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">acetyl-L-carnitine</synonym>
    <synonym language="english" coder="">O-acetyl-L-carnitine </synonym>
    <synonym language="english" coder="">O-Acetylcarnitine</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Acilen</name>
      <company>IFI (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Actigeron</name>
      <company>Bago (Chile)</company>
    </international-brand>
    <international-brand>
      <name>Branigen</name>
      <company>Sigma-Tau (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Branitil</name>
      <company>OFF (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Ceredor</name>
      <company>IRBI (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Fertilix</name>
      <company>Fortbenton (Argentina)</company>
    </international-brand>
    <international-brand>
      <name>Lacetilina</name>
      <company>Pentafarma (Portugal)</company>
    </international-brand>
    <international-brand>
      <name>Laremide</name>
      <company>Lafedar (Argentina)</company>
    </international-brand>
    <international-brand>
      <name>Levocetile</name>
      <company>Korea United (Philippines)</company>
    </international-brand>
    <international-brand>
      <name>Maxoza</name>
      <company>Sun (India)</company>
    </international-brand>
    <international-brand>
      <name>Memorx IQ Plus</name>
      <company>Gruppo Medica (Philippines)</company>
    </international-brand>
    <international-brand>
      <name>Memovigor</name>
      <company>Euro-Pharma (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Neurex</name>
      <company>Beta (Argentina)</company>
    </international-brand>
    <international-brand>
      <name>Neuroactil </name>
      <company>Bago (Argentina)</company>
    </international-brand>
    <international-brand>
      <name>Nicetile</name>
      <company>Sigma-Tau (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Normobren</name>
      <company>Medosan (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Phototrop</name>
      <company>Tubilux (Italy)</company>
    </international-brand>
    <international-brand>
      <name>Zibren</name>
      <company>Sigma-Tau (Italy)</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Ammonium Compounds</category>
      <mesh-id>D064751</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Diet, Food, and Nutrition</category>
      <mesh-id>D000066888</mesh-id>
    </category>
    <category>
      <category>Food</category>
      <mesh-id>D005502</mesh-id>
    </category>
    <category>
      <category>Food and Beverages</category>
      <mesh-id>D019602</mesh-id>
    </category>
    <category>
      <category>Growth Substances</category>
      <mesh-id>D006133</mesh-id>
    </category>
    <category>
      <category>Micronutrients</category>
      <mesh-id>D018977</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Nitrogen Compounds</category>
      <mesh-id>D017672</mesh-id>
    </category>
    <category>
      <category>Nootropic Agents</category>
      <mesh-id>D018697</mesh-id>
    </category>
    <category>
      <category>Onium Compounds</category>
      <mesh-id>D009861</mesh-id>
    </category>
    <category>
      <category>Physiological Phenomena</category>
      <mesh-id>D010829</mesh-id>
    </category>
    <category>
      <category>Psychoanaleptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychostimulants, Agents Used for Adhd and Nootropics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quaternary Ammonium Compounds</category>
      <mesh-id>D000644</mesh-id>
    </category>
    <category>
      <category>Trimethyl Ammonium Compounds</category>
      <mesh-id>D050337</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes>
    <atc-code code="N06BX12">
      <level code="N06BX">Other psychostimulants and nootropics</level>
      <level code="N06B">PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS</level>
      <level code="N06">PSYCHOANALEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB08842.pdf?1375801208</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-2.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.9</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.55e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(3R)-3-(acetyloxy)-4-(trimethylazaniumyl)butanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>acetyl-L-carnitine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>203.238</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>203.115758031</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C9H17NO4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RDHQFKQIGNGIED-MRVPVSSYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>66.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>72.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>20.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.09</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Very soluble in water and alcohol.</value>
      <source>From The Merck Index.</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>145Â°C</value>
      <source>From The Merck Index.</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>57589</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>7045767</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427117</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C02571</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5406074</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Acetylcarnitine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1697733</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/acetyl-l-carnitine/supplements.htm</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0000106</id>
      <name>Solute carrier family 22 member 5</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16105</ref-id>
            <pubmed-id>10525100</pubmed-id>
            <citation>Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.</citation>
          </article>
          <article>
            <ref-id>A17877</ref-id>
            <pubmed-id>17965255</pubmed-id>
            <citation>Kobayashi D, Tamai I, Sai Y, Yoshida K, Wakayama T, Kido Y, Nezu J, Iseki S, Tsuji A: Transport of carnitine and acetylcarnitine by carnitine/organic cation transporter (OCTN) 2 and OCTN3 into epididymal spermatozoa. Reproduction. 2007 Nov;134(5):651-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O76082" source="Swiss-Prot">
        <name>Solute carrier family 22 member 5</name>
        <general-function>Symporter activity</general-function>
        <specific-function>Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.</specific-function>
        <gene-name>SLC22A5</gene-name>
        <locus>5q31</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>21-41
143-163
173-193
198-218
233-253
258-278
342-362
374-394
407-427
431-451
463-483
489-509</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.04</theoretical-pi>
        <molecular-weight>62751.08</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10969</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC22A5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3273741</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O76082</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>High-affinity sodium-dependent carnitine cotransporter</synonym>
          <synonym>OCTN2</synonym>
          <synonym>Organic cation/carnitine transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000212|Solute carrier family 22 member 5
MRDYDEVTAFLGEWGPFQRLIFFLLSASIIPNGFTGLSSVFLIATPEHRCRVPDAANLSS
AWRNHTVPLRLRDGREVPHSCRRYRLATIANFSALGLEPGRDVDLGQLEQESCLDGWEFS
QDVYLSTIVTEWNLVCEDDWKAPLTISLFFVGVLLGSFISGQLSDRFGRKNVLFVTMGMQ
TGFSFLQIFSKNFEMFVVLFVLVGMGQISNYVAAFVLGTEILGKSVRIIFSTLGVCIFYA
FGYMVLPLFAYFIRDWRMLLVALTMPGVLCVALWWFIPESPRWLISQGRFEEAEVIIRKA
AKANGIVVPSTIFDPSELQDLSSKKQQSHNILDLLRTWNIRMVTIMSIMLWMTISVGYFG
LSLDTPNLHGDIFVNCFLSAMVEVPAYVLAWLLLQYLPRRYSMATALFLGGSVLLFMQLV
PPDLYYLATVLVMVGKFGVTAAFSMVYVYTAELYPTVVRNMGVGVSSTASRLGSILSPYF
VYLGAYDRFLPYILMGSLTILTAILTLFLPESFGTPLPDTIDQMLRVKGMKHRKTPSHTR
MLKDGQERPTILKSTAF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009938|Solute carrier family 22 member 5 (SLC22A5)
ATGCGGGACTACGACGAGGTGACCGCCTTCCTGGGCGAGTGGGGGCCCTTCCAGCGCCTC
ATCTTCTTCCTGCTCAGCGCCAGCATCATCCCCAATGGCTTCACCGGCCTGTCCTCCGTG
TTCCTGATAGCGACCCCGGAGCACCGCTGCCGGGTGCCGGACGCCGCGAACCTGAGCAGC
GCCTGGCGCAACCACACTGTCCCACTGCGGCTGCGGGACGGCCGCGAGGTGCCCCACAGC
TGCCGCCGCTACCGGCTCGCCACCATCGCCAACTTCTCGGCGCTTGGGCTGGAGCCGGGG
CGCGACGTGGACCTGGGGCAGCTGGAGCAGGAGAGCTGTCTGGATGGCTGGGAGTTCAGT
CAGGACGTCTACCTGTCCACCATTGTGACCGAGCAAGACAGTGGGGCCTACAATGCTATG
AAAAACAGGATGGGAAAGAAGCCTGCTCTCTGCCTTCCTGCCCAGTGGAACCTGGTGTGT
GAGGACGACTGGAAGGCCCCACTCACAATCTCCTTGTTCTTCGTGGGTGTGCTGTTGGGC
TCCTTCATTTCAGGGCAGCTGTCAGACAGGTTTGGCCGGAAGAATGTGCTGTTCGTGACC
ATGGGCATGCAGACAGGCTTCAGCTTCCTGCAGATCTTCTCGAAGAATTTTGAGATGTTT
GTCGTGCTGTTTGTCCTTGTAGGCATGGGCCAGATCTCCAACTATGTGGCAGCATTTGTC
CTGGGGACAGAAATTCTTGGCAAGTCAGTTCGTATAATATTCTCTACGTTAGGAGTGTGC
ATATTTTATGCATTTGGCTACATGGTGCTGCCACTGTTTGCTTACTTCATCCGAGACTGG
CGGATGCTGCTGGTGGCGCTGACGATGCCGGGGGTGCTATGCGTGGCACTCTGGTGGTTC
ATCCCTGAGTCCCCCCGATGGCTCATCTCTCAGGGACGATTTGAAGAGGCAGAGGTGATC
ATCCGCAAGGCTGCCAAAGCCAATGGGATTGTTGTGCCTTCCACTATCTTTGACCCGAGT
GAGTTACAAGACCTAAGTTCCAAGAAGCAGCAGTCCCACAACATTCTGGATCTGCTTCGA
ACCTGGAATATCCGGATGGTCACCATCATGTCCATAATGCTGTGGATGACCATATCAGTG
GGCTATTTTGGGCTTTCGCTTGATACTCCTAACTTGCATGGGGACATCTTTGTGAACTGC
TTCCTTTCAGCGATGGTTGAAGTCCCAGCATATGTGTTGGCCTGGCTGCTGCTGCAATAT
TTGCCCCGGCGCTATTCCATGGCCACTGCCCTCTTCCTGGGTGGCAGTGTCCTTCTCTTC
ATGCAGCTGGTACCCCCAGACTTGTATTATTTGGCTACAGTCCTGGTGATGGTGGGCAAG
TTTGGAGTCACGGCTGCCTTTTCCATGGTCTACGTGTACACAGCCGAGCTGTATCCCACA
GTGGTGAGAAACATGGGTGTGGGAGTCAGCTCCACAGCATCCCGCCTGGGCAGCATCCTG
TCTCCCTACTTCGTTTACCTTGGTGCCTACGACCGCTTCCTGCCCTACATTCTCATGGGA
AGTCTGACCATCCTGACAGCCATCCTCACCTTGTTTCTCCCAGAGAGCTTCGGTACCCCA
CTCCCAGACACCATTGACCAGATGCTAAGAGTCAAAGGAATGAAACACAGAAAAACTCCA
AGTCACACAAGGATGTTAAAAGATGGTCAAGAAAGGCCCACAATCCTTAAAAGCACAGCC
TTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carnitine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cation</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>symporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modified amino acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of intestinal epithelial structure maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quorum sensing involved in interaction with host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-dependent organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0004785</id>
      <name>Solute carrier family 22 member 21</name>
      <organism>Mouse</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17877</ref-id>
            <pubmed-id>17965255</pubmed-id>
            <citation>Kobayashi D, Tamai I, Sai Y, Yoshida K, Wakayama T, Kido Y, Nezu J, Iseki S, Tsuji A: Transport of carnitine and acetylcarnitine by carnitine/organic cation transporter (OCTN) 2 and OCTN3 into epididymal spermatozoa. Reproduction. 2007 Nov;134(5):651-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9WTN6" source="Swiss-Prot">
        <name>Solute carrier family 22 member 21</name>
        <general-function>Cation:cation antiporter activity</general-function>
        <specific-function>Sodium-ion independent, medium affinity carnitine transporter. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 746.</specific-function>
        <gene-name>Slc22a21</gene-name>
        <locus/>
        <cellular-location>Peroxisome membrane</cellular-location>
        <transmembrane-regions>21-41
143-163
173-193
198-218
233-253
258-278
345-365
377-397
410-430
434-454
466-486
492-512</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>63320.215</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="10090">Mouse</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9WTN6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22AL_MOUSE</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Octn3</synonym>
          <synonym>Organic cation/carnitine transporter 3</synonym>
          <synonym>Slc22a9</synonym>
          <synonym>Solute carrier family 22 member 9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013317|Solute carrier family 22 member 21
MLDYDEVTAFLGEWGTFQRLIFFLLSASIIPNGFTGLSAVFLTAIPEHRCRIPDTVNLSS
AWRNHSIPMETKDGPEVPQKCRRYRLATIANFSELGLEPGRDVDLEQLEQENCLDGWEYD
KDIFLSTIVTEWDLVCKDDWKAPLTTSFFYVGVLLGSFISGQLSDRFGRKNILFLTMAMH
TGFSFIQVFSVNFEMFTLLYTLVGMGHISNYVAAFVLGTEMLSKSVRIIFATLGVCIFFA
FGFMVLPLFAYFIREWRRLLLAITLPGVLCGALWWFIPESPRWLISQGRIKEAEVIIRKA
AKINGIVAPSTIFDPSETNKLQDDSSKKPQSHHIYDLVRTPNIRILTIMSIILWLTISVG
YFGLSLDTPNLNGNIYVNCFLLAAVEVPAYVLAWLLLQHVSRRYSMAGSLFLGGSVLLLV
QLVPSDLHYLSTTLVMVGKFGITSAYSMVYVYTAELYPTVVRNMGVGVSSTASRLGSILS
PYFVYLGAYDRRLPYILMGSLTILTAIITLFFPESSGVSLPETIDEMQKVKKLKQRQSLS
KKGSPKESKGNVSRTSRTSEPKGF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013318|Solute carrier family 22 member 21 (Slc22a21)
ATGCTTGACTACGACGAGGTGACCGCCTTCCTGGGCGAGTGGGGGACCTTCCAGCGCCTC
ATCTTCTTCCTGCTCAGCGCCAGCATCATCCCCAATGGCTTTACTGGGTTGTCAGCCGTG
TTCCTGACGGCGATCCCGGAGCACCGTTGCCGGATACCAGACACCGTGAACCTGAGCAGC
GCGTGGCGCAACCACAGTATCCCGATGGAGACGAAGGACGGACCAGAGGTGCCTCAGAAA
TGCCGCCGCTACCGACTGGCCACCATCGCCAACTTCTCTGAGCTAGGGCTGGAGCCGGGA
CGGGACGTGGACCTGGAGCAGCTGGAGCAGGAGAACTGCCTGGATGGCTGGGAGTACGAC
AAGGACATCTTCCTGTCCACCATCGTGACAGAGTGGGACCTGGTGTGTAAGGATGACTGG
AAAGCCCCACTCACCACCTCCTTCTTTTACGTGGGTGTGCTCTTAGGCTCCTTCATTTCG
GGACAGCTCTCAGACAGGTTTGGTCGCAAGAATATCTTGTTTTTGACCATGGCCATGCAC
ACCGGATTCAGCTTCATACAAGTCTTCTCTGTGAACTTCGAGATGTTTACTCTGCTCTAT
ACCCTTGTTGGAATGGGACATATATCCAACTACGTGGCAGCATTTGTCCTGGGAACAGAA
ATGCTTTCCAAGTCAGTTAGAATTATATTCGCCACCTTAGGAGTTTGCATATTTTTTGCG
TTTGGCTTCATGGTGCTGCCTCTGTTTGCATACTTCATCAGAGAGTGGAGGAGGCTGCTG
CTGGCAATTACTTTACCAGGCGTGCTGTGTGGGGCTCTCTGGTGGTTCATCCCTGAGTCC
CCACGATGGCTCATCTCTCAAGGCCGAATTAAAGAGGCAGAGGTGATCATCCGCAAAGCT
GCCAAAATCAATGGGATTGTTGCACCTTCCACTATCTTCGATCCAAGCGAGACCAATAAA
TTACAAGACGATAGTTCCAAGAAGCCCCAGTCGCACCACATTTATGATCTGGTCCGAACA
CCAAATATCAGGATCCTCACCATCATGTCTATAATCCTGTGGCTGACCATATCAGTGGGC
TATTTTGGACTATCTCTTGACACTCCTAACTTGAATGGGAACATCTATGTGAACTGCTTC
CTACTGGCGGCTGTTGAAGTCCCAGCCTATGTGCTGGCCTGGCTGTTGTTGCAGCATGTG
TCCCGGCGTTATTCTATGGCTGGTTCCCTCTTCCTGGGTGGCAGTGTCCTTCTCTTAGTA
CAACTGGTGCCTTCAGACCTACATTACTTGTCTACTACCCTGGTGATGGTGGGGAAGTTT
GGAATCACCTCTGCCTACTCCATGGTCTATGTGTACACAGCTGAGCTGTACCCCACTGTG
GTCAGAAACATGGGTGTGGGGGTCAGCTCCACAGCATCCCGCCTTGGCAGCATCCTGTCT
CCCTACTTTGTTTATCTAGGTGCCTATGACCGCCGCCTACCTTATATCCTCATGGGAAGT
CTAACCATCCTGACAGCTATCATCACTTTATTCTTCCCAGAGAGTTCTGGGGTTTCTCTC
CCAGAAACCATTGACGAGATGCAAAAAGTCAAAAAACTAAAACAAAGGCAATCCCTAAGC
AAGAAAGGGTCCCCGAAGGAGTCTAAAGGAAATGTATCCCGAACCTCCCGAACCTCCGAA
CCTAAAGGCTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of peroxisomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carnitine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carnitine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>